Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.56 |
| ▸ | PPARG | P37231 | 6/20 | 0.56 |
| ▸ | PPARA | Q07869 | 5/20 | 0.56 |
| ▸ | VDR | P11473 | 4/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | THRA | P10827 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237180 | 0.91 | PPARD (0.63) | PPARDPPARGPPARAVDRMRGPRX4 | |
| SCHEMBL6265930 | 0.86 | PPARD (0.54) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL6241083 | 0.83 | PPARD (0.52) | PPARDPPARGPPARAVDRESR1 | |
| SCHEMBL6240042 | 0.81 | PPARD (0.59) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL6233940 | 0.80 | PPARD (0.58) | PPARDPPARGPPARAVDRMRGPRX4 | |
| SCHEMBL6265932 | 0.80 | PPARD (0.47) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL6236452 | 0.79 | PPARD (0.83) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL6237550 | 0.77 | PPARD (0.81) | PPARDPPARGPPARAVDRESR1 | |
| SCHEMBL6236846 | 0.77 | PPARD (0.74) | PPARDPPARGPPARAVDRFFAR1 | |
| SCHEMBL6237881 | 0.77 | PPARD (0.67) | PPARDPPARGPPARAVDRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189895-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-06-08 | — | — | EP | claimed |
| US-6710063-B1 | Activators of PPAR delta | SMITHKLINE BEECHAM CORPORATION | 2004-03-23 | — | — | US | claimed |
| US-10426757-B2 | Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170258772-A1 | COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL AND/OR NON-STEM PROGENITOR CELL FUNCTION | HOWARD HUGHES MEDICAL INSTITUTE | 2017-09-14 | — | — | US | disclosed |
| EP-1189895-B8 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1189895-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6723740-B2 | ADMINISTERING THERAPEUTIC AMOUNT OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST TO LOWER TRIGLYCERIDES | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6710063-B1 | Activators of PPAR delta | SMITHKLINE BEECHAM CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | CHAO ESTHER YU-HSUAN (US) | 2003-10-30 | — | — | US | disclosed |
| EP-1189895-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001000603-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426757-B2 | Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function | FABP2, ALPG, ALPI | PPARD 2842/4885PPARG 786/4885PPARA 1257/4885 |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | PPARA, PPARD, PPARG | PPARD 2/4885PPARG 3/4885PPARA 1/4885 |
| US-20170258772-A1 | COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL AND/OR NON-STEM PROGENITOR CELL FUNCTION | FABP2, ALPG, ALPI | PPARD 2842/4885PPARG 786/4885PPARA 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.